Compare PRLD & ISRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRLD | ISRL |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 79.3M |
| IPO Year | 2020 | 2023 |
| Metric | PRLD | ISRL |
|---|---|---|
| Price | $1.68 | $12.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 1.3K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $10,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $231.49 |
| Revenue Growth | ★ 250.00 | N/A |
| 52 Week Low | $0.61 | $11.22 |
| 52 Week High | $4.22 | $14.00 |
| Indicator | PRLD | ISRL |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 53.09 |
| Support Level | $1.32 | $12.34 |
| Resistance Level | $1.69 | $12.38 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 91.02 | 100.00 |
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.